The study was not supported. Dr Raja has received research support from Eli Lilly, Janssen-Cilag, and Pfizer. He has also been on the speakers' bureau and a consultant for the following companies: Astra-Zeneca, Bristol-Myers Squibb, Eli Lilly, Janssen-Cilag, Glaxo-Smith-Kline, Sanofi-Synthelabo, and Wyeth. His participation at scientific meetings and congresses has been sponsored by Astra-Zeneca, Bristol-Myers Squibb, Eli Lilly, Janssen-Cilag, Glaxo-Smith-Kline, Lundbeck, Novartis, Organon, Pfizer, Roche, and Sanofi-Synthelabo. Dr Azzoni has been on the speakers' bureau and a consultant for Janssen-Cilag. Her participation at scientific meetings and congresses has been sponsored by Astra-Zeneca, Eli Lilly, Janssen-Cilag, Lundbeck, Novartis, and Organon.
Are antidepressants warranted in the treatment of patients who present suicidal behavior?†
Article first published online: 17 NOV 2008
Copyright © 2008 John Wiley & Sons, Ltd.
Human Psychopharmacology: Clinical and Experimental
Volume 23, Issue 8, pages 661–668, December 2008
How to Cite
Raja, M. and Azzoni, A. (2008), Are antidepressants warranted in the treatment of patients who present suicidal behavior?. Hum. Psychopharmacol. Clin. Exp., 23: 661–668. doi: 10.1002/hup.985
- Issue published online: 27 NOV 2008
- Article first published online: 17 NOV 2008
- Manuscript Accepted: 17 SEP 2008
- Manuscript Received: 17 APR 2008
- mood stabilizers;
The aim of the study was to ascertain the clinical course of patients admitted to a psychiatric intensive care unit (PICU) just after a suicide attempt (SA) and to evaluate the effectiveness of 2nd generation antipsychotics and mood stabilizers in these patients.
We examined all the 129 patients discharged in a three-year period, who had been admitted after a SA and considered in the analysis the 82 cases non-transferred (in the first 72 h) to other PICUs for administrative or logistic reasons. Among them, 47 received a complete neuropsychiatric assessment. We distinguished between patients who had been treated with Antidepressants (AD) or not in the three months preceding hospitalization.
We treated all patients with mood stabilizers and 2nd generation antipsychotics. Only one patient was treated with AD in the course of current hospitalization. Both cases treated and not treated with AD before admission improved significantly, especially in symptoms of anxiety and depression, as well as in suicidality. The suicidal risk abated without AD treatment.
In patients with impending suicide risk, AD should not be considered standard treatment. Mood stabilizers and 2nd generation antipsychotics can be effective. Copyright © 2008 John Wiley & Sons, Ltd.